Related Experiment Video

Updated: May 3, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.3K

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast

Jian Kang, C Marcelo Sergio, Robert L Sutherland

  • 1The Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, Sydney, NSW, Australia. Liz.Musgrove@glasgow.ac.uk.

BMC Cancer
|January 22, 2014
PubMed
Abstract

Insights

Targeting MYC in breast cancer is difficult. Researchers found that inhibiting cyclin-dependent kinase 1 (CDK1) selectively kills MYC-dependent breast cancer cells, offering a potential new therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • MYC is a challenging therapeutic target in breast cancer due to difficulties in direct inhibition.
  • Identifying synthetic-lethal genes in MYC-dependent cancers offers an alternative therapeutic strategy.
  • Cell cycle kinases have emerged as potential MYC synthetic-lethal genes.

Purpose of the Study:

  • To investigate the therapeutic potential of specific cyclin-dependent kinase (CDK) inhibition in MYC-driven breast cancer.
  • To determine if CDK inhibition is synthetically lethal in MYC-dependent breast cancer cells.

Main Methods:

  • Depleted MYC expression using small interfering RNA (siRNA) in 26 human breast cancer cell lines.
  • Assessed cell proliferation via BrdU incorporation and classified cell lines based on MYC dependence.
  • Inhibited CDKs (CDK4/6, CDK2, CDK1) individually using RNAi or small molecule inhibitors.

Main Results:

  • MYC knockdown sensitivity varied among breast cancer cell lines, correlating with MYC expression and phosphorylation.
  • CDK4/6 inhibition (PD0332991) showed sensitivity in MYC-independent, not MYC-dependent, cell lines.
  • CDK1 inactivation selectively induced apoptosis and reduced viability in MYC-dependent cells, independent of p53, via BIM upregulation.

Conclusions:

  • CDK1 inactivation demonstrates selective efficacy against MYC-dependent breast cancer cells.
  • CDK1 inhibition warrants further investigation as a potential therapeutic strategy for MYC-driven breast cancer.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

7.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

2.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
100.8K